Nexentis Technologies (NASDAQ:NXTS – Get Free Report) and Contineum Therapeutics (NASDAQ:CTNM – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, valuation, profitability, risk, earnings and institutional ownership.
Profitability
This table compares Nexentis Technologies and Contineum Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nexentis Technologies | N/A | -304.79% | -178.91% |
| Contineum Therapeutics | N/A | -24.73% | -23.51% |
Insider & Institutional Ownership
61.2% of Nexentis Technologies shares are held by institutional investors. 6.5% of Nexentis Technologies shares are held by insiders. Comparatively, 7.9% of Contineum Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nexentis Technologies | $210,000.00 | 9.87 | -$4.00 million | ($96.07) | -0.01 |
| Contineum Therapeutics | $50.00 million | 10.40 | -$59.98 million | ($1.73) | -7.99 |
Nexentis Technologies has higher earnings, but lower revenue than Contineum Therapeutics. Contineum Therapeutics is trading at a lower price-to-earnings ratio than Nexentis Technologies, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Nexentis Technologies has a beta of 1.85, indicating that its share price is 85% more volatile than the S&P 500. Comparatively, Contineum Therapeutics has a beta of 0.75, indicating that its share price is 25% less volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent recommendations and price targets for Nexentis Technologies and Contineum Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nexentis Technologies | 1 | 0 | 0 | 0 | 1.00 |
| Contineum Therapeutics | 1 | 1 | 4 | 0 | 2.50 |
Contineum Therapeutics has a consensus target price of $20.80, suggesting a potential upside of 50.51%. Given Contineum Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Contineum Therapeutics is more favorable than Nexentis Technologies.
Summary
Contineum Therapeutics beats Nexentis Technologies on 9 of the 13 factors compared between the two stocks.
About Nexentis Technologies
N2OFF, Inc., an agri-food tech company, engages in the development and sale of eco-friendly green solutions for the food industry to enhance food safety and shelf life of fresh produce. Its products are based on proprietary blend of food acids combined with various oxidizing agent-based sanitizers and low concentrated fungicides for cleaning, sanitizing, and controlling pathogens on fresh produce that are safer for human consumption and extend their shelf life by reducing their decay. The company’s products include SavePROTECT or PeroStar, a processing aid for post-harvest application that is added to fruit and vegetable wash water; and SF3HS and SF3H, a post-harvest cleaning and sanitizing solution to control plant and foodborne pathogens. It also offers SpuDefender for controlling post-harvest potato sprouts; and FreshProtect to control spoilage-creating microorganisms on post-harvest citrus fruit. The company was formerly known as Save Foods, Inc. and changed its name to N2OFF, Inc. in March 2024. N2OFF, Inc. was incorporated in 2009 and is headquartered in Hod HaSharon, Israel.
About Contineum Therapeutics
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.
Receive News & Ratings for Nexentis Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nexentis Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
